Your search returned 11 results.

Results
	1.	Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. [electronic resource] by Li, Jing Gupta, Manish Jin, Denise Xin, Yan Visich, Jennifer Allison, David E Producer: 20130408 In: Cancer chemotherapy and pharmacology vol. 71 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. [electronic resource] by Allison, David E Gourlay, Steven G Koren, Eugene Miller, Robert M Fox, Judith A Producer: 20020823 In: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. [electronic resource] by Han, Kelong Jin, Jin Maia, Mauricio Lowe, John Sersch, Martina A Allison, David E Producer: 20150512 In: The AAPS journal vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Population pharmacokinetics of bevacizumab in cancer patients with external validation. [electronic resource] by Han, Kelong Peyret, Thomas Marchand, Mathilde Quartino, Angelica Gosselin, Nathalie H Girish, Sandhya Allison, David E Jin, Jin Producer: 20170606 In: Cancer chemotherapy and pharmacology vol. 78 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. [electronic resource] by Adams, Camellia W Allison, David E Flagella, Kelly Presta, Leonard Clarke, Janet Dybdal, Noel McKeever, Kathleen Sliwkowski, Mark X Producer: 20060510 In: Cancer immunology, immunotherapy : CII vol. 55 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	A guide to rational dosing of monoclonal antibodies. [electronic resource] by Bai, Shuang Jorga, Karin Xin, Yan Jin, Denise Zheng, Yanan Damico-Beyer, Lisa A Gupta, Manish Tang, Meina Allison, David E Lu, Dan Zhang, Yi Joshi, Amita Dresser, Mark J Producer: 20120507 In: Clinical pharmacokinetics vol. 51 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. [electronic resource] by Han, Kelong Peyret, Thomas Quartino, Angelica Gosselin, Nathalie H Gururangan, Sridharan Casanova, Michela Merks, Johannes H M Massimino, Maura Grill, Jacques Daw, Najat C Navid, Fariba Jin, Jin Allison, David E Producer: 20161005 In: British journal of clinical pharmacology vol. 81 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. [electronic resource] by Agus, David B Gordon, Michael S Taylor, Charles Natale, Ronald B Karlan, Beth Mendelson, David S Press, Michael F Allison, David E Sliwkowski, Mark X Lieberman, Gracie Kelsey, Stephen M Fyfe, Gwen Producer: 20050505 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 23 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. [electronic resource] by Agus, David B Sweeney, Christopher J Morris, Michael J Mendelson, David S McNeel, Douglas G Ahmann, Frederick R Wang, Jin Derynck, Mika K Ng, Kimmie Lyons, Benjamin Allison, David E Kattan, Michael W Scher, Howard I Producer: 20070327 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. [electronic resource] by Khawli, Leslie A Goswami, Sirj Hutchinson, Ryan Kwong, Zephania W Yang, Jihong Wang, Xiangdan Yao, Zhenling Sreedhara, Alavattam Cano, Tony Tesar, Devin Nijem, Ihsan Allison, David E Wong, Pin Yee Kao, Yung-Hsiang Quan, Cynthia Joshi, Amita Harris, Reed J Motchnik, Paul Producer: 20110322 In: mAbs vol. 2 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. [electronic resource] by Gordon, Michael S Matei, Daniela Aghajanian, Carol Matulonis, Ursula A Brewer, Molly Fleming, Gini F Hainsworth, John D Garcia, Agustin A Pegram, Mark D Schilder, Russell J Cohn, David E Roman, Lynda Derynck, Mika K Ng, Kimmie Lyons, Benjamin Allison, David E Eberhard, David A Pham, Thinh Q Dere, Randall C Karlan, Beth Y Producer: 20060926 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)